APEX Ventures

APEX Ventures operates from Vienna as one of Austria’s more visible deep-tech investors, with a thesis built around backing technical founders at the earliest stages of company formation. The fund has carved out a clear identity in a region where deep-tech specialists are relatively scarce and where many high-quality science and engineering teams need patient early capital before they are ready for larger European or international rounds.

The healthcare focus runs through AI/ML in healthcare, medical devices and MedTech, and diagnostics. Within that, APEX tends to favor companies applying machine learning to imaging and diagnostic problems, novel medical device platforms emerging from European research environments, and diagnostic technologies that combine technical novelty with clear clinical applications. The fund is comfortable being one of the first institutional investors and engaging with companies before they have fully built out commercial teams or international expansion plans.

Check sizes run from $250K to $1M across pre-seed and seed rounds. That positioning makes APEX a natural lead or co-lead for early European deep-tech rounds, often working alongside university tech transfer offices, angel networks, and other early-stage European funds. Founders should expect diligence that engages seriously with the underlying science and IP, alongside commercial questions about market size, regulatory pathway, and credibility of early customer signals.

The team brings investing, operating, and scientific backgrounds, with relationships across Austrian, German, and broader European university and research ecosystems. That network is a meaningful part of what the fund offers portfolio companies, particularly for those whose progression depends on access to clinical advisors, regulatory expertise, or follow-on capital from larger European venture firms. The fund is comfortable working with first-time founders coming out of academic environments and is candid about the operational gaps such teams typically need to fill.

For founders, working with APEX means an investor that is technically engaged and willing to be patient with the realities of building deep-tech and medical device companies. Post-investment support tends to focus on hiring, follow-on syndication, regulatory strategy, and connecting portfolio companies with clinical and customer partners across Europe. The fund is a less natural fit for software-only companies without meaningful technical depth or for founders who want a fast, US-style fundraising process. It is a strong fit for European deep-tech and medical device teams who want a credible early lead with the technical literacy to engage with their underlying work and the patience to support a multi-year path from formation to clinical or commercial validation. APEX’s working style tends to be substantive and direct, with a clear preference for founders who can defend their plans on their merits.